Table 1 Summary of the GWAS included in this TSMR study
Variables | Data codes | Source of sample ethnicity | Sample size | Size of SNPs | Year of publication |
|---|---|---|---|---|---|
T2DM | ebi-a-GCST006867 | Europeans | 655,666 | 5,030,727 | 2018 |
T2DM | ebi-a-GCST005413 | Europeans | 70,127 | 14,277,791 | 2018 |
T2DM | GCST90006934 | Europeans | 22,326 | 8,919,079 | 2020 |
Severe insulin resistant T2DM | GCST90026414 | Europeans | 3,874 | 5,397,362 | 2021 |
T2DM | GCST90026417 | Europeans | 12,230 | 5,399,457 | 2021 |
T2DM | GCST90043636 | Europeans | 456,348 | 11,842,647 | 2021 |
T1DM | ebi-a-GCST005536 | Europeans | 29,652 | 101,101 | 2015 |
T1DM | ebi-a-GCST010681 | Europeans | 24,840 | 12,783,129 | 2020 |
T1DM | ebi-a-GCST90000529 | Europeans | 17,685 | 7,740,245 | 2021 |
T1DM | ebi-a-GCST90014023 | Europeans | 520,580 | 59,999,551 | 2021 |
T1DM | ebi-a-GCST90018925 | Europeans | 457,695 | 24,182,422 | 2021 |
Osteonecrosis | R9_M13_OSTEONECROSIS | Europeans | 359,399 | 20,169,843 | 2021 |